Enanta Pharmaceuticals to Present at SVB Leerink 10th Annual Global Healthcare Conference

Rhea-AI Summary

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) announced that Jay R. Luly, Ph.D., its CEO, will present at the SVB Leerink 10^th Annual Global Healthcare Conference on February 25, 2021, at 8:40 am ET. The presentation will be accessible via live webcast on Enanta's website, with a replay available for 90 days. Enanta focuses on developing small molecule drugs for viral infections and liver diseases, with clinical candidates for respiratory syncytial virus, hepatitis B, and non-alcoholic steatohepatitis. Their research is funded by royalties from hepatitis C products developed with AbbVie.

Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will present at the SVB Leerink 10^th Annual Global Healthcare Conference on Thursday, February 25, 2021 at 8:40 am ET.

A live webcast of the presentation will be accessible by visiting the “Events and Presentations” section on the “Investors” page of Enanta’s website at www.enanta.com. A replay of the webcast will be available following the presentation and will be archived for approximately 90 days.

About Enanta

Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. Enanta’s research and development efforts have produced clinical candidates for the following disease targets: respiratory syncytial virus (RSV), hepatitis B virus (HBV) and non-alcoholic steatohepatitis (NASH). Enanta is also conducting research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19).

Enanta’s research and development activities are funded by royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie. Glecaprevir, a protease inhibitor discovered by Enanta, is sold by AbbVie in numerous countries as part of its leading treatment for chronic HCV infection under the tradenames MAVYRET^® (U.S.) and MAVIRET^® (ex-U.S.) (glecaprevir/pibrentasvir). Please visit www.enanta.com for more information.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210218005937/en/

FAQ

What is the date and time of Enanta Pharmaceuticals' presentation at the SVB Leerink Conference?

Enanta Pharmaceuticals' presentation will take place on February 25, 2021, at 8:40 am ET.

Who is presenting for Enanta Pharmaceuticals at the upcoming conference?

Jay R. Luly, Ph.D., President and CEO of Enanta Pharmaceuticals, will be presenting.

How can I access the webcast of Enanta Pharmaceuticals' conference presentation?

The live webcast can be accessed on the 'Events and Presentations' section of Enanta's website.

What areas of drug development does Enanta Pharmaceuticals focus on?

Enanta focuses on developing small molecule drugs for viral infections and liver diseases such as RSV, HBV, and NASH.

How is Enanta Pharmaceuticals funded for its research and development activities?

Enanta's research is funded by royalties from hepatitis C products developed in collaboration with AbbVie.